SLC7A11 and cancer: Indeed, xCT has attracted the attention of pharmaceutical companies that are trying to develop new inhibitors for cancer treatment [50], since the currently available xCT inhibitory molecules, including SAS, Sorafenib, Erastin, and IKE, present some limitations regarding their use in vivo, offering poor pharmacokinetics and bioavailability.